Research Topics
| M J MorrisSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris
Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, NY 10065, USA
Ann Oncol 23:2714-9. 2012....- Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancerElizabeth R Dennis
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 30:519-24. 2012..Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure... - Novel strategies and therapeutics for the treatment of prostate carcinomaM J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 89:1329-48. 2000..Angiogenesis and tumor invasion also have been targeted, as have cell cycling and signal transduction. Strategies promoting apoptosis and augmenting differentiation are also under study... - Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
Curr Urol Rep 6:163-70. 2005..In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development... - Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapyMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
Clin Cancer Res 11:3210-6. 2005..We tested the hypothesis that serial fluorodeoxyglucose positron emission tomography (FDG-PET) scans can serve as an outcome measure for patients with castrate metastatic prostate cancer treated with antimicrotubule chemotherapy... - Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Appl Immunohistochem Mol Morphol 13:6-13. 2005..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2... - Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumorsMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 13:2707-13. 2007..This phase I trial tested the hypothesis that J591 could be used as a vascular targeting platform for patients with nonprostate solid tumors... - Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
Curr Oncol Rep 6:222-9. 2004..In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development... - Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 11:7454-61. 2005..The relationship among dose, safety, pharmacokinetics, and antibody-dependent cellular cytotoxicity (ADCC) activation for unlabeled J591 has not been explored... - Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer CenterMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, 10021, New York, NY, USA
Crit Rev Oncol Hematol 46:S21-31. 2003..High-throughput preclinical assays of gene expression are being developed to enhance selection of drug sequences and combinations for clinical testing... - Clinical approaches to osseous metastases in prostate cancerMichael J Morris
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Oncologist 8:161-73. 2003..These approaches combine those listed above with tumor-directed targeting of osseous disease and manipulation of the biology that underlies the cancer's relationship to bone... - High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinomaMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 100:1868-75. 2004..Pulse-dosed calcitriol and dexamethasone may maximize tolerability and efficacy. The authors examined the toxicity of pulse-dosed calcitriol with zoledronate and with the addition of dexamethasone at the time of disease progression... - Novel therapies for the treatment of prostate cancer: current clinical trials and development strategiesMichael J Morris
Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
Surg Oncol 11:13-23. 2002..Investigators use a clinical states model as a framework for matching specific agents with the needs of the treatment population and the biology of the tumor at any given point in the natural history of the disease... - Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 27:2436-42. 2009..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam... - Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancerMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Eur Urol 56:237-44. 2009..Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth... - Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castrationO Smaletz
Department of Medicine, Division of Solid Tumor, Memorial Sloan-Kettering Cancer Center, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA
Ann Oncol 14:1518-24. 2003..CONCLUSIONS: The phase II dose of BMS-247550 combined with EMP is 35 mg/m(2) over 3 h every 3 weeks. This combination is safe and >/= 50% post-therapy declines in PSA were seen in 11 of 12 patients (92%)... - A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancerMichael J Morris
Department of Medicine Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 178:2378-83; discussion 2383-4. 2007..We defined the antitumor effects of bortezomib alone and in combination with prednisone in patients with progressive, castration resistant metastatic prostate cancer... - HER-2 profiling and targeting in prostate carcinomaMichael J Morris
Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer 94:980-6. 2002.... - Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directionsGretchen A Gignac
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 178:S30-5. 2007..We focused on the current management and novel investigational strategies for the chemonaïve patient population with castration resistant metastatic disease... - Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf
Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 26:2959-65. 2008..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers... - Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancerMichael J Morris
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 59:913-8. 2002..Post-treatment changes in the SUV tend to correlate with changes in PSA... - Prostate cancer clinical trial end points: "RECIST"ing a step backwardsHoward I Scher
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 11:5223-32. 2005..To relate clinical issues to the clinical manifestations of prostate cancers across disease states using the eligibility and outcome criteria defined by Response Evaluation Criteria in Solid Tumors (RECIST)... - Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila
Department of Medicine, Joan and Sanford E Weill College of Medicine of Cornell University, Ithaca, NY, USA
J Clin Oncol 28:1496-501. 2010..This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy... - Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Lancet 375:1437-46. 2010..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease... - Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancerKouta Ito
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Ann Intern Med 152:621-9. 2010..Objective: To assess the cost-effectiveness of measuring bone mineral density (BMD) before initiating ADT followed by alendronate therapy in men with localized prostate cancer... - Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancerMichael J Morris
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:679-83. 2002..Current randomized trials are using the highest daily dose established in this study given by shorter infusion periods (i.e., 7 mg/kg/day for 5-7 days) to enhance the antitumor activity of standard cytotoxic drugs... - Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapyNeeta Pandit-Taskar
Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 49:1066-74. 2008..An analysis was performed to assess lesion detectability by (111)In-J591 gamma-camera imaging compared with standard imaging methods and the effect of increasing antibody mass on lesion detectability, biodistribution, and dosimetry... - Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trialsMark T Fleming
Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Nat Clin Pract Oncol 3:658-67. 2006..It is important to recognize that there are a range of clinical benefits to patients that can improve the quality and possibly the duration of survival, independent of PSA... - Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 13:1775-82. 2007..To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules... - Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PETBradley J Beattie
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 51:183-92. 2010.... - Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of BabelGretchen A Gignac
Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 113:966-74. 2008..PFS, however, is vulnerable to inter-study design variability. The authors sought to identify and quantify this variability and the resultant error in PFS across prostate cancer clinical trials... - Novel tracers and their development for the imaging of metastatic prostate cancerAndrea B Apolo
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Nucl Med 49:2031-41. 2008..Hence, although many promising agents are available for testing, such studies would benefit from closer collaboration between those in the fields of medical oncology and nuclear medicine... - Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustineMichael J Morris
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Weill Medical College, New York, New York, USA
Urology 60:1111. 2002..We recommend that patients receiving weekly docetaxel, with or without estramustine, have frequent treatment breaks and be evaluated with computed tomography of the chest every 8 weeks... - Germline BRCA mutations denote a clinicopathologic subset of prostate cancerDavid J Gallagher
Clinical Genetics Service, Department of Medicine, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 16:2115-21. 2010..Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined... - Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Genitourin Cancer 7:51-7. 2009..This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC)... - Imaging therapeutic response in human bone marrow using rapid whole-body MRIDouglas Ballon
Department of Radiology, Weill Medical College of Cornell University, New York, New York 10021, USA
Magn Reson Med 52:1234-8. 2004..Examples presented include the evaluation of therapeutic response in bone marrow during cytotoxic therapy for leukemia and metastatic prostate cancer and during cytokine administration for marrow mobilization prior to stem cell harvest... - Cardiopulmonary exercise test interpretation using age-matched controls to evaluate exertional dyspneaJoshua M Sill
Pulmonary Disease Critical Care Medicine Service, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Road, Fort Sam Houston, TX 78234 6200, USA
Mil Med 174:1177-82. 2009..This study evaluated interpretation of maximal CPET in a young adult cohort with known pulmonary disorders using published reference values compared to age-matched normal controls... - Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus
Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
J Clin Oncol 25:675-81. 2007..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy... - Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:5816-24. 2007.... - (11)C-acetate PET imaging in prostate cancerMichael J Morris
Eur J Nucl Med Mol Imaging 34:181-4. 2007 - Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge ConferencePhilip W Kantoff
Lank Center for Genitourinary Oncology, Boston, Massachusetts, USA
J Urol 178:S5-8; quiz S4. 2007 - Expression of prostate-specific membrane antigen in renal cortical tumorsHikmat A Al-Ahmadie
Department of Pathology, University of Chicago, Chicago, IL, USA
Mod Pathol 21:727-32. 2008.... - Progressive vocal cord dysfunction subsequent to a chlorine gas exposurePatrick F Allan
Pulmonary Medicine Flight, Wilford Hall Medical Center, Lackland AFB, San Antonio, Texas, USA
J Voice 20:291-6. 2006..This article constitutes the first case of a single antecedent chlorine exposure inducing progressive vocal cord dysfunction... - A phenolate-induced trans influence: crystallographic evidence for unusual asymmetric coordination of an alpha-diimine in ternary complexes of iron(III) possessing biologically relevant hetero-donor N-centered tripodal ligandsMusa S Shongwe
Department of Chemistry, College of Science, Sultan Qaboos University, P O Box 36, Al Khod 123, Muscat, Sultanate of Oman
Inorg Chem 44:3070-9. 2005....
Research Grants
- Radioimmunotherapy for Prostate CancerMichael Morris; Fiscal Year: 2007..The acquisition of these skills combined with the completion of the research plan will allow the candidate to pursue such research independently. ..